Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Anti-Inhibitor Coagulant Complex · Feiba, FEIBA

Plasma-derived product · Protein replacement · developed by Takeda Pharmaceuticals America

Approved FDA, Dec 1979
TAK Developer
1 Registered trials

What is Anti-Inhibitor Coagulant Complex?

Anti-Inhibitor Coagulant Complex (FEIBA) is a plasma-derived concentrate of non-activated factors II, IX and X and mainly activated factor VII. These components interact with plasma coagulation factors and platelets to increase thrombin generation. It is used in hemophilia patients with inhibitors to factor VIII or factor IX, for bleeding control, perioperative management and routine prophylaxis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Feiba, FEIBA
Drug type
Plasma-derived product
Mechanism
Protein replacement
Pathways
thrombin generation, coagulation cascade
Therapy area
Hematology
Developer
Takeda Pharmaceuticals America, Inc. (TAK)
FDA status
Approved as Feiba (December 21, 1979), BLA101447 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 27, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04563520 Phase 3 Hemophilia A Withdrawn TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hemophilia A

More from Takeda Pharmaceuticals America

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind Anti-Inhibitor Coagulant Complex

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.